Vitamin D, Omega-3, and Combination Vitamins B, C and Zinc Supplementation for the Treatment and Prevention of COVID-19

Hospital de la Soledad

Overview

The NUTROVID Factorial Trials The purpose of the NUTROVID-Prevent and NUTROVID-Treat Factorial Trials is to determine whether Vitamin B Complex, Vitamin C, and Zinc; Vitamin D; and Omega3, taken at dosages approximating recommended dosages, can reduce the risk of COVID-19 infection, hospitalization, mortality.

Inadequate vitamin intake is common in Mexico. Vitamin deficiency is hypothesized as a risk factor for COVID-19 infection and severe outcomes. Specifically, Vitamin D has been hypothesized as a regulator of the inflammatory cytokine response; Vitamin C may help reduce the risk of a cytokine storm and support the immune system; Vitamin B reduces pro-inflammatory cytokine levels, helps improve respiratory function, reduces hypercoagulability, and promotes endothelial structural integrity; Resolvins, derived from Omega3s, are a type of specialized pro-resolving lipid autacoid mediators hypothesized to prevent cytokine storms. Elemental Zinc is hypothesized to inhibit the replication of viruses. The NUTROVID-Prevent and NUTROVID-Treat Factorial Trials are testing the efficacy of these supplements (Vitamins B, C, D, Zinc, and Omega 3) when used over a 60 day period among those who test positive (Treat) and negative (Prevent) for SARS-COV-2 via a PCR test. The NUTROVID Trials utilize an innovative and cost-efficient approach, leveraging the existing infrastructure of the hospital system in San Luis Potosí province of Mexico. For NUTROVID-Treat, we aim to enroll \~1,800 adults who have recently tested positive for SARS-Cov-2 and who have given informed consent. These \~1,800 adult females and males age 18 or older will be enrolled and randomized into the NUTROVID Treat Factorial Trial's 2x2x2 arms, in which 50% of the population will have a chance to receive any combination of the 3 supplement formulations; the other 50% will receive the respective placebos. Those who test negative will be randomized into the NUTROVID-Prevent Factorial Trial's 2x2x2 arms, in which 50% of the population will have a chance to receive any combination of the 3 supplement formulations; the other 50% will receive the respective placebos. For NUTROVID-Prevent, we also aim to recruit \~1,800 adults, females and males. Hospital staff will review medical records for vital events and conduct patient and family follow-up until \~November 2021.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

DOUBLE

Conditions

Covid19

Interventions

Vitamin DDIETARY_SUPPLEMENT

Daily 4000 IU Vitamin D for 60 days

Omega DHA / EPADIETARY_SUPPLEMENT

Daily 1000mg Omega DHA/EPA for 60 days

Vitamin C, Vitamin B complex and Zinc AcetateDIETARY_SUPPLEMENT

Combination 1000 mg Vitamin C, Vitamin B complex\*\* and Zinc Acetate, 100 mg/day for 60 days \*\*(Vitamin B complex components: B12=1 mg; B6=50 mg; B9=2.5 mg; B1=100 mg; B2=100 mg; B3=14 mg; B7=50 mg)

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Positive SARS-CoV-2 Test group (Target enrollment: N=1,800) NUTROVID Treat Trial: Adult men/women recently diagnosed with COVID-19 (positive PCR test for SARS-CoV-2 coronavirus) within \<=5 days of symptom onset; and satisfying one of these risk factors: \>=50 years old; or Diabetic \& \>=40 years old; or Obese \& \>=40 years old. Negative SARS-CoV-2 Test group (Target enrollment: N=1,800) NUTROVID Prevent Trial: Adult men/women recently tested negative for COVID-19 (negative PCR test for SARS-CoV-2 coronavirus); and satisfying one of these risk factors: \>=50 years old; or Diabetic \& \>=40 years old; or Obese \& \>=40 years old. Signed Informed Consent Form Exclusion Criteria: * Patients requiring immediate intubation or deemed likely to die within 48 hours. * Patients deemed likely for transfer to an ICU within 48 hours. * Patients currently taking oral corticosteroids for any reason at the time of presentation for care. * Patients included in any other interventional trial. * Uncontrolled bacterial superinfection. * Severe chronic kidney disease (stage 4) or requiring dialysis (i.e. eGFR \< 30). * Pregnant women or women who are breastfeeding. * Immunocompromised patients. * Any patient with recent treatment (past 30 days) of immunosuppressive agents including (but not restricted to) DMARDs, corticosteroids, antibody therapy, intravenous immunoglobulins etc. * Patients with acute myocardial infarction.

Locations (1)

Hospital de Soledad

San Luis Potosí City, San Luis Potosí, Mexico

Outcomes

Primary Outcomes

Covid infection rate (PREVENT Trial only)

1.a. Incidence of positive PCR at \~1 month and \~2 months; 1.b. Incidence of symptomatic positive PCR and asymptomatic positive PCR at 1 month and 2 months.

Time frame: 30 and 60 days

Incidence of severe outcome (TREAT Trial only)

1.a. Incidence of severe outcome (mortality or ICU admission or intubation) up to 30 days. 1.b. Incidence of severe outcome (mortality or ICU admission or intubation) from 30-60 days. 1.c. Incidence of severe outcome (mortality or ICU admission or intubation), from 30 days to \~ November 2021. 1.d. Incidence of severe outcome (mortality or ICU admission or intubation), from 60 days to \~ November 2021.

Time frame: 1.a. 1-30 days; 1.b. 30-60; 1.c. 30 days to ~November 2021; 1.d. 60 days to ~ November 2021

Secondary Outcomes

Incidence of hospitalization and death (PREVENT Trial only)

2.a. Incidence of hospitalization, follow-up to \~ November 2021. 2.b. Incidence of severe outcome (mortality or ICU admission or intubation), follow-up to \~November 2021. 2.c. Incidence of death, follow-up to \~November 2021.

Time frame: 1-10 months

Length of hospitalization and death after discharge (TREAT Trial only)

2.a. Length of hospitalization for admissions less than 30 days from baseline versus for admissions after 30 days from baseline. 2.b. \[If available\] Incidence of hospital readmission after discharge, follow-up to \~November 2021. 2.c. Incidence of death after discharge, follow-up to \~November 2021.

Time frame: 2.a. 1-30 days; 2.b. 1 day(s) to ~November 2021, 2.c. 30 days to ~November 2021

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.